Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.

Emily R FinchLaura J JankeLie LiMonique A PaytonDavid A JenkinsKristine R CrewsMary V Relling Seth E Karol

Published in: Pediatric blood & cancer (2021)

Based on the results of our preclinical murine studies, we conclude that dasatinib is unlikely to increase the osteonecrotic effects of dexamethasone in ALL regimens.

Keyphrases

acute lymphoblastic leukemia
high dose
low dose
chronic myeloid leukemia
high glucose
diabetic rats
allogeneic hematopoietic stem cell transplantation
case control
stem cells
oxidative stress
endothelial cells
acute myeloid leukemia
bone marrow